NASDAQ$OTLK
Outlook Therapeutics Inc · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
Reported business highlights and financial results.
Outlook Therapeutics reported a net loss attributable to common stockholders of $18.5 million, or $0.62 per basic and diluted share, for the fiscal first quarter ended December 31, 2019. The company is advancing towards a new BLA submission to the FDA for ONS-5010 in 2021, with a potential commercial launch in 2022.
- Phase 3 development program for ONS-5010 continues to make progress.
- Patient recruitment for the NORSE 2 study is expected to be completed by the end of May 2020.
- Topline data for the NORSE 1 study is expected to be announced in August 2020.
- Agreements with BioLexis and MTTR were entered into to streamline the Company’s capital structure and regain 100% ownership of any future net profits for ONS-5010.
Headline financials
Revenue & EPS history
Outlook Therapeutics · Revenue · Quarterly
$1.07M
Forward guidance
Outlook Therapeutics is focused on advancing ONS-5010 towards a BLA submission to the FDA in 2021 and a potential commercial launch in 2022.
Tailwinds
- Ongoing patient recruitment for the NORSE 2 study, expected to be completed by the end of May 2020.
- Planned announcement of topline data for the NORSE 1 study in August 2020.
- Agreements from the FDA on three Special Protocol Assessments (SPAs) for three additional registration clinical trials for its ongoing Phase 3 program for ONS-5010.
- Intention to complete development of ONS-5010 for submission to the FDA as a new Biologics License Application (BLA) for the treatment of wet AMD, DME and BRVO.
- Intention to seek the requisite stockholder approvals under agreements with BioLexis and MTTR
Headwinds
- Risks associated with developing pharmaceutical product candidates.
- Risks of conducting clinical trials.
- Risks in obtaining necessary regulatory approvals.
- The company had cash of $1.3 million at December 31, 2019, compared to $8.0 million at September 30, 2019.
- Net loss attributable to common stockholders of $18.5 million for the quarter ended December 31, 2019, compared to a net loss of $9.9 million for the same period last year.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2020
+5.1%
Avg return
Earnings day
+6.9%
Avg return
5 days after
-0.7%
Avg return
30 days after
61%
25 / 41 earnings
Positive
+48.5%
Q2 2019
Best reaction
-14.6%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | +1.3% | -0.9% | — | |
| Q1 2026 | -13.9% | -15.7% | -31.4% | |
| Q4 2025 | -2.9% | -11.6% | -73.6% | |
| Q3 2025 | +14.1% | +23.5% | -51.2% | |
| Q2 2025 | +1.2% | +9.9% | -0.6% | |
| Q1 2025 | +1.6% | -7.9% | -14.7% | |
| Q4 2024 | +9.4% | +11.2% | +17.1% | |
| Q3 2024 | -0.9% | -7.6% | -16.5% | |
| Q2 2024 | -0.9% | +7.4% | +3.6% | |
| Q1 2024 | +21.2% | +13.0% | +3.0% | |
| Q4 2023 | +4.2% | +8.2% | -18.5% | |
| Q3 2023 | -3.1% | -16.9% | -85.3% | |
| Q2 2023 | +3.5% | +16.5% | +46.1% | |
| Q1 2023 | -3.3% | -7.5% | -15.8% | |
| Q4 2022 | +6.9% | +4.0% | +15.8% | |
| Q3 2022 | -3.4% | +5.9% | -4.2% | |
| Q2 2022 | +7.4% | +2.7% | -37.1% | |
| Q1 2022 | +3.7% | +8.1% | +36.3% | |
| Q4 2021 | -4.2% | -1.4% | -14.6% | |
| Q3 2021 | -14.6% | -16.2% | -1.6% | |
| Q2 2021 | +16.0% | +21.2% | +34.1% | |
| Q1 2021 | -0.4% | -4.0% | -9.5% | |
| Q4 2020 | +1.3% | -4.6% | -13.1% | |
| Q3 2020 | +5.2% | +14.2% | -54.5% | |
| Q2 2020 | +1.9% | -1.9% | +40.4% | |
| Q1 2020 | +0.0% | -1.1% | -35.1% | |
| Q4 2019 | -1.7% | -53.0% | -11.1% | |
| Q3 2019 | -4.2% | -8.9% | -17.8% | |
| Q2 2019 | +48.5% | +191.3% | +125.2% | |
| Q1 2019 | +28.2% | +28.2% | -5.8% | |
| Q4 2018 | +24.5% | +42.9% | +34.7% | |
| Q3 2018 | +1.2% | -8.8% | +0.0% | |
| Q2 2018 | +2.7% | +1.1% | -13.3% | |
| Q1 2018 | +4.3% | +3.5% | -19.0% | |
| Q4 2017 | +0.0% | -7.9% | -4.8% | |
| Q3 2017 | +0.5% | +3.0% | +77.8% | |
| Q2 2017 | -8.7% | -34.1% | -24.5% | |
| Q1 2017 | +10.6% | +2.1% | -1.2% | |
| Q4 2016 | +28.6% | +40.3% | +59.8% | |
| Q2 2016 | +28.6% | +40.3% | +59.8% | |
| Q3 2016 | -3.9% | -5.3% | -8.1% | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro